Celcuity (CELC) Analyst Average of $160 Suggests +167% Upside – Can the Stock Get There?
Key Takeaways
- The $160 central target is the arithmetic mean of roughly ten current, verified analyst price targets, not a published official consensus.
- The stock trades near $60, so reaching $160 would require a very large move of roughly 167% from recent levels.
- Individual targets range from about $134 to $177 among recently updated ratings, with an older sell-side low near $110.
- The strongest support is the U.S. launch of REVTORPYK (gedatolisib), the company's first FDA-approved drug.
- The biggest risks are a post-approval sell-off, widening losses, heavy short interest, and convertible-debt dilution.
Analyst Price Targets and Consensus View
Celcuity Inc. (CELC) is a clinical-to-commercial stage biotechnology company in Minneapolis developing gedatolisib, a dual PI3K/mTOR inhibitor for advanced breast cancer. Reviewing current, individually attributed targets — including H.C. Wainwright ($155, October 2026), J.P. Morgan ($157, September 2026), Leerink Partners ($147, October 2026), Needham ($134, September 2026), Guggenheim ($175, August 2026), Craig-Hallum ($173, August 2026), Citizens JMP ($177, August 2026), Wells Fargo ($166, August 2026), LifeSci Capital ($165, August 2026), and Stifel ($150, August 2026) — produces a mean of roughly $160. In my view, this arithmetic average offers a useful reference point even though it is not an official consensus figure.
The spread is wide, from about $134 to $177, reflecting genuine disagreement over how quickly gedatolisib sales will ramp. Most covering analysts rate the stock Buy, yielding a "Strong Buy" to "Moderate Buy" stance overall, but the range is unusually broad because valuation depends on early launch execution. Notably, Zacks Research cut CELC to "strong sell" in mid-October 2026, while Needham and Stifel trimmed targets — underscoring that not every sell-side view is bullish. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of mid-October 2026, CELC trades near $60, down sharply from its 52-week high of $151.02 set in May 2026. That means the $160 target sits roughly 167% above the latest price — a very large required move that would effectively require the stock to more than double. Reaching it likely depends on REVTORPYK building real prescription momentum and on the company widening its label into the PIK3CA-mutant population, not merely on retaining current expectations.
What Could Support a Move Toward the Target
The core bull case is now commercial rather than purely clinical. The FDA approved REVTORPYK in July 2026 for HR-positive, HER2-negative advanced breast cancer, and the drug became commercially available on September 30, 2026. Unlike selective PI3K inhibitors from Novartis (NVS) and Pfizer (PFE)-partnered rivals, gedatolisib works in the PIK3CA wild-type majority. Management has cited a multi-billion-dollar addressable market, and Celcuity filed a supplemental application in August 2026 to expand into PIK3CA-mutant patients. Roughly $754 million in cash provides funding runway.
What Could Prevent the Target From Being Reached
The stock has fallen roughly 60% from its May 2026 peak even after approval and launch. Investors have focused on tolerability (high rates of mouth inflammation in studies), a delayed commercial launch, and a second-quarter net loss of about $78.9 million, with EPS (earnings per share) missing consensus. The company carries $575 million in convertible notes due 2032, creating future dilution risk, and short interest is high at over 20% of shares outstanding. With essentially no revenue history, any slow launch or disappointing first sales figures could compress valuation further. Competition, cash burn, and execution risk in a first-ever commercial launch all remain material.
Technical Levels and Market Structure
The chart has deteriorated markedly. CELC trades below its 50-day moving average near $84 and its 200-day moving average near $100–104, with the RSI (relative strength index) in oversold territory near 30. The prior $70–71 shelf has broken, and the $85–88 zone — former support — now acts as resistance. The 52-week low near $46.51 marks the next major downside reference, while any durable recovery would first need to reclaim the mid-$80s before the $100+ zone becomes relevant again. From what I see, monitoring these levels alongside broader market sentiment remains important.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon. The key near-term catalyst is the next earnings report, estimated for November 11, 2026, which will offer the first meaningful read on REVTORPYK prescriptions and revenue. Investors should also track the supplemental label-expansion filing for PIK3CA-mutant patients, updates on the VIKTORIA-2 and prostate-cancer trials, quarterly cash burn, and any further analyst target revisions, which have recently been trending lower. I’m watching this closely for signs of momentum shifts.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. For a volatile, catalyst-driven name like CELC, supplementing fundamental research with real-time signal monitoring can help identify changes in momentum as they develop.
Final Assessment
Can CELC reach $160? The target is a legitimate, analyst-derived average of current buy-rated price objectives, and it sits far above the recent price — meaning the stock would need to more than double. The bull case rests on successful commercialization of REVTORPYK and label expansion, while the bear case points to a sharp post-approval decline, widening losses, dilution, and elevated short interest. Analysts disagree widely on the path, with targets spanning roughly $134 to $177. Reaching $160 is not a forecast but a scenario contingent on launch execution and clinical-regulatory progress that remains unproven.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CELC in -9.04% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CELC declined for three days, in 238 of 280 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CELC turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 36 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CELC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (84.746) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company develops novel diagnostic tests
Industry Biotechnology
Advertisement